Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$7.26 USD
+0.35 (5.07%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.28 +0.02 (0.28%) 6:00 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Cash flow Statements
Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.02 | -108.18 | -180.97 | -102.68 | -123.85 |
Depreciation/Amortization & Depletion | 11.65 | 2.71 | 2.76 | 1.37 | 1.43 |
Net Change from Assets/Liabilities | -5.61 | -6.82 | -21.63 | 4.52 | 2.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 38.52 | 32.76 | 42.15 | 26.93 | 56.83 |
Net Cash From Operating Activities | -33.46 | -79.53 | -157.69 | -69.86 | -63.46 |
Property & Equipment | -0.72 | -0.29 | -0.30 | -5.67 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 5.88 | -59.68 | -84.53 | -150.84 | 7.88 |
Other Investing Activities | -11.86 | -0.66 | -7.20 | -1.68 | -0.02 |
Net Cash from Investing Activities | -6.71 | -60.63 | -103.87 | -158.19 | 7.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.90 | 2.43 | 221.11 | 194.38 | 236.87 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -10.03 | 0.00 | 0.00 | 0.00 | -0.13 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 6.99 |
Net Cash from Financing Activities | -5.13 | 2.43 | 221.11 | 194.38 | 243.73 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -45.30 | -137.73 | -40.45 | -33.67 | 188.05 |
Cash at Beginning of Period | 94.17 | 231.90 | 272.35 | 306.02 | 117.97 |
Cash at End of Period | 48.88 | 94.17 | 231.90 | 272.35 | 306.02 |
Diluted Net EPS | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 |
Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -10.03 | -10.75 | -78.02 | -51.15 | -37.70 |
Depreciation/Amortization & Depletion | 9.69 | 4.85 | 11.65 | 6.70 | 1.24 |
Net Change from Assets/Liabilities | -4.98 | -10.76 | -5.61 | -25.04 | -11.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.56 | -1.94 | 38.52 | 21.71 | 13.09 |
Net Cash From Operating Activities | -2.76 | -18.60 | -33.46 | -47.77 | -34.50 |
Property & Equipment | -0.10 | -0.01 | -0.72 | -0.66 | -0.74 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 10.75 | 49.25 | 5.88 | 12.07 | 31.85 |
Other Investing Activities | -0.04 | 0.00 | -11.86 | -11.86 | -11.86 |
Net Cash from Investing Activities | 10.61 | 49.23 | -6.71 | -0.45 | 19.25 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -17.32 | -12.27 | 4.90 | 3.93 | 2.78 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -6.00 | -2.78 | -10.03 | -3.48 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -23.32 | -15.05 | -5.13 | 0.45 | 2.78 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -15.47 | 15.58 | -45.30 | -47.78 | -12.47 |
Cash at Beginning of Period | 48.88 | 48.88 | 94.17 | 94.17 | 94.17 |
Cash at End of Period | 33.41 | 64.46 | 48.88 | 46.40 | 81.71 |
Diluted Net EPS | 0.01 | -0.07 | -0.19 | -0.09 | -0.08 |